Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices 6707

six WD40 repeats, and a heparinbinding domain. In vitro, over 

expression of AAMP–1 promotes tumor 

cell invasion and metastasis as well as 

angiogenesis. AAMP–1 was later found 

to be over expressed in endothelial 

cells, cytotrophoblasts, and poorly 

differentiated colon adenocarcinoma 

cells found in lymphatics. In addition, 

gene expression studies have shown 

that AAMP–1 is over expressed in breast 

and gastrointestinal tumors. 

The issued patents claim proteins, 

polypeptides, and recombinant 

polyclonal antibodies specific to 

AAMP–1 and their use in diagnostic 

and therapeutic applications. The 

antibodies are specific and can detect 

formalin-fixed antigen and SDSdenatured antigen. 

These antibodies can be used for 

detailed expression studies of AAMP–1 

in different cancer cell lines. The 

antibodies could also be used to 

promote cell adhesion to a substrate, 

promote tissue acceptance of prostheses, 

and promote wound healing. The 

antibodies could also be used to detect 

AAMP–1 in patient’s sera as a useful 

diagnostic marker for multiple 

carcinomas including high nuclear 

grade ductal carcinoma in situ (Clinical 

Cancer Research Dec 2002 8:3788–95).

Dated: January 31, 2005. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 05–2394 Filed 2–7–05; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Special Emphasis Panel, RFA CA–

05–002 and CA–05–006–IMAT. 

Date: March 9–10, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Hilton, 620 Perry 

Parkway, Gaithersburg, MD 20877. 

Contact Person: Sherwood Githens, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, National 

Cancer Institute, Division of Extramural 

Activities, 6116 Executives Blvd., Bethesda, 

MD 20892, 301/435–1822, 

githenss@mail.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: February 2, 2005. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committees Policy.

[FR Doc. 05–2349 Filed 2–7–05; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Special Emphasis Panel Special 

Emphasis Panel or Review of R25 

Applications. 

Date: March 30–31, 2005. 

Time: 6 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Wyndham City Center Hotel, 1143 

New Hampshire Ave., NW., Washington, DC 

20037. 

Contact Person: David E. Maslow, PhD, 

Chief, Resources and Training Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, National Institutes 

of Health, 6116 Executive Boulevard—Room 

8117, Bethesda, MD 20892–7405, (301) 496–

2330.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: February 2, 2005. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 05–2350 Filed 2–7–05; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Special Emphasis Panel 

Transdiciplinary Research on Energetics and 

Cancer. 

Date: March 2–3, 2005. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Select Bethesda, 8120 

Wisconsin Ave., Bethesda, MD 20814. 

Contact Person: Mary Jane Slesinski, PhD, 

Scientific Review Administrator, Special 

Review and Resources Branch, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, Room 8045, Bethesda, 

MD 20892, 301/594–1566.